MX2019008064A - Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr / cas9 con secuencias guía triples. - Google Patents
Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr / cas9 con secuencias guía triples.Info
- Publication number
- MX2019008064A MX2019008064A MX2019008064A MX2019008064A MX2019008064A MX 2019008064 A MX2019008064 A MX 2019008064A MX 2019008064 A MX2019008064 A MX 2019008064A MX 2019008064 A MX2019008064 A MX 2019008064A MX 2019008064 A MX2019008064 A MX 2019008064A
- Authority
- MX
- Mexico
- Prior art keywords
- cas9
- crispr
- modifications
- exon skipping
- guide sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
- C12N5/0659—Satellite cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/066—Tenocytes; Tendons, Ligaments
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Epidemiology (AREA)
Abstract
La edición genómica mediada por CRISPR/Casg tiene un potencial tánico para el tratamiento de enfermedades genéticas, como la distrofia muscular de Duchenne (DMD). que es causada por mutaciones en el gen de la distrofina. En la presente, mediante el uso de tres promotores para dirigir la expresión del mismo ARN gula de DMD, se logró una forma más sólida y segura de edición genómica en un modelo de ratón humanizado para DMD con una eliminación en el exón 50 y en un modelo de perro ?Ex50-MD.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762442606P | 2017-01-05 | 2017-01-05 | |
US201762544449P | 2017-08-11 | 2017-08-11 | |
US201762596298P | 2017-12-08 | 2017-12-08 | |
PCT/US2018/012558 WO2018129296A1 (en) | 2017-01-05 | 2018-01-05 | Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008064A true MX2019008064A (es) | 2020-07-20 |
Family
ID=61193018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008064A MX2019008064A (es) | 2017-01-05 | 2018-01-05 | Estrategia optimizada para modificaciones de omisión de exones mediante el uso de crispr / cas9 con secuencias guía triples. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20190338311A1 (es) |
EP (1) | EP3565897A1 (es) |
JP (1) | JP2020503869A (es) |
KR (1) | KR102606174B1 (es) |
CN (1) | CN110506115A (es) |
AU (1) | AU2018205521A1 (es) |
BR (1) | BR112019013962A2 (es) |
CA (1) | CA3048635A1 (es) |
CL (1) | CL2019001882A1 (es) |
CO (1) | CO2019008181A2 (es) |
CR (1) | CR20190326A (es) |
DO (1) | DOP2019000179A (es) |
EC (1) | ECSP19056408A (es) |
IL (1) | IL267786A (es) |
JO (1) | JOP20190166A1 (es) |
MA (1) | MA47239A (es) |
MX (1) | MX2019008064A (es) |
PE (1) | PE20191357A1 (es) |
PH (1) | PH12019501561A1 (es) |
SG (1) | SG11201906147VA (es) |
WO (1) | WO2018129296A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
JPWO2018179578A1 (ja) * | 2017-03-30 | 2020-02-06 | 国立大学法人京都大学 | ゲノム編集によるエクソンスキッピング誘導方法 |
WO2019136216A1 (en) * | 2018-01-05 | 2019-07-11 | The Board Of Regents Of The University Of Texas System | Therapeutic crispr/cas9 compositions and methods of use |
US20210261962A1 (en) * | 2018-06-21 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy |
SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3108289A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2020122104A1 (ja) * | 2018-12-11 | 2020-06-18 | 国立大学法人京都大学 | ゲノムdnaに欠失を誘導する方法 |
WO2020142714A1 (en) * | 2019-01-04 | 2020-07-09 | Exonics Therapeutics, Inc. | Aav expression cassette and aav vectors comprising the same |
US10947534B2 (en) * | 2019-03-07 | 2021-03-16 | The Trustees Of Columbia University In The City Of New York | RNA-guided DNA integration using Tn7-like transposons |
JP2022526669A (ja) * | 2019-04-12 | 2022-05-25 | デューク ユニバーシティ | ジストロフィン機能を修復するためのCRISPR/Casをベースにした塩基編集組成物 |
EP3952925A4 (en) * | 2019-04-12 | 2024-01-24 | Univ California | COMPOSITIONS AND METHODS FOR MODIFYING DYSTROPHIN GENES |
US20210047649A1 (en) | 2019-05-08 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crispr/cas all-in-two vector systems for treatment of dmd |
KR102264115B1 (ko) * | 2019-05-10 | 2021-06-14 | 한국과학기술연구원 | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 |
CN110499333A (zh) * | 2019-08-01 | 2019-11-26 | 广州德赫生物科技有限公司 | 用于修复dmd基因突变的核酸序列及系统 |
US20240091379A1 (en) * | 2019-10-11 | 2024-03-21 | Yale University | Compositions and methods for upregulating isoforms of dystrophin as therapy for duchenne muscular dystrophy (dmd) |
CN114846146B (zh) * | 2019-10-29 | 2024-04-12 | 基恩科雷有限责任公司 | 用于增加CRISPR/Cas12f1系统的效率的工程化引导RNA及其用途 |
CN111172191B (zh) * | 2020-02-21 | 2020-12-22 | 浙江大学 | 一种高效基因敲除载体及其应用 |
CN115011598A (zh) * | 2020-09-02 | 2022-09-06 | 西湖大学 | 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
WO2023159103A1 (en) * | 2022-02-17 | 2023-08-24 | The Board Of Regents Of The University Of Texas System | CRISPR/SpCas9 VARIANT AND METHODS FOR ENHANCED CORRECTON OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS |
KR20230134098A (ko) * | 2022-03-10 | 2023-09-20 | 주식회사 진코어 | 듀센 근이영양증 치료를 위한 유전자 편집 시스템 및 이를 이용한 질병 치료 방법 |
CN115820642B (zh) * | 2022-11-11 | 2023-10-10 | 昆明理工大学 | 一种用于治疗杜氏肌营养不良症的CRISPR-Cas9系统 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1737966B1 (en) * | 2004-04-02 | 2012-05-09 | Board of Regents, The University of Texas System | Cancer specific promoters |
PE20150336A1 (es) | 2012-05-25 | 2015-03-25 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn |
EP3004370A4 (en) * | 2013-06-05 | 2017-01-11 | Duke University | Rna-guided gene editing and gene regulation |
EP3116533B1 (en) * | 2014-03-12 | 2020-08-12 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
CA2959130A1 (en) * | 2014-08-11 | 2016-02-18 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by crispr/cas9-mediated gene editing |
WO2016089866A1 (en) * | 2014-12-01 | 2016-06-09 | President And Fellows Of Harvard College | Rna-guided systems for in vivo gene editing |
JP6832280B2 (ja) * | 2015-01-16 | 2021-02-24 | ユニバーシティ オブ ワシントンUniversity of Washington | 新規のマイクロジストロフィンおよび使用の関連する方法 |
EP3280803B1 (en) * | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
WO2016174056A1 (en) * | 2015-04-27 | 2016-11-03 | Genethon | Compositions and methods for the treatment of nucleotide repeat expansion disorders |
EP3368063B1 (en) * | 2015-10-28 | 2023-09-06 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
WO2017095967A2 (en) * | 2015-11-30 | 2017-06-08 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
US20170362635A1 (en) * | 2016-06-20 | 2017-12-21 | University Of Washington | Muscle-specific crispr/cas9 editing of genes |
-
2017
- 2017-06-16 JO JOP/2019/0166A patent/JOP20190166A1/ar unknown
-
2018
- 2018-01-05 BR BR112019013962-1A patent/BR112019013962A2/pt unknown
- 2018-01-05 AU AU2018205521A patent/AU2018205521A1/en active Pending
- 2018-01-05 MX MX2019008064A patent/MX2019008064A/es unknown
- 2018-01-05 KR KR1020197022753A patent/KR102606174B1/ko active IP Right Grant
- 2018-01-05 US US16/476,137 patent/US20190338311A1/en active Pending
- 2018-01-05 CR CR20190326A patent/CR20190326A/es unknown
- 2018-01-05 JP JP2019536508A patent/JP2020503869A/ja active Pending
- 2018-01-05 WO PCT/US2018/012558 patent/WO2018129296A1/en unknown
- 2018-01-05 MA MA047239A patent/MA47239A/fr unknown
- 2018-01-05 CN CN201880010288.7A patent/CN110506115A/zh active Pending
- 2018-01-05 EP EP18704637.0A patent/EP3565897A1/en active Pending
- 2018-01-05 CA CA3048635A patent/CA3048635A1/en active Pending
- 2018-01-05 SG SG11201906147VA patent/SG11201906147VA/en unknown
- 2018-01-05 PE PE2019001384A patent/PE20191357A1/es unknown
-
2019
- 2019-07-02 IL IL267786A patent/IL267786A/en unknown
- 2019-07-02 PH PH12019501561A patent/PH12019501561A1/en unknown
- 2019-07-05 DO DO2019000179A patent/DOP2019000179A/es unknown
- 2019-07-05 CL CL2019001882A patent/CL2019001882A1/es unknown
- 2019-07-29 CO CO2019008181A patent/CO2019008181A2/es unknown
- 2019-08-06 EC ECSENADI201956408A patent/ECSP19056408A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JOP20190166A1 (ar) | 2019-07-02 |
PH12019501561A1 (en) | 2019-09-09 |
ECSP19056408A (es) | 2019-09-30 |
KR102606174B1 (ko) | 2023-11-27 |
IL267786A (en) | 2019-09-26 |
CO2019008181A2 (es) | 2019-10-31 |
CA3048635A1 (en) | 2018-07-12 |
CN110506115A (zh) | 2019-11-26 |
PE20191357A1 (es) | 2019-10-01 |
MA47239A (fr) | 2019-11-13 |
KR20190100967A (ko) | 2019-08-29 |
DOP2019000179A (es) | 2019-11-15 |
JP2020503869A (ja) | 2020-02-06 |
EP3565897A1 (en) | 2019-11-13 |
CL2019001882A1 (es) | 2019-10-04 |
AU2018205521A1 (en) | 2019-07-18 |
US20190338311A1 (en) | 2019-11-07 |
SG11201906147VA (en) | 2019-08-27 |
BR112019013962A2 (pt) | 2020-02-11 |
CR20190326A (es) | 2019-10-02 |
WO2018129296A1 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501561A1 (en) | Optimized strategy for exon skipping modifications using crispr/cas9 with triple guide sequences | |
MX2018008733A (es) | Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo. | |
NZ630900A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
ZA202206102B (en) | Excision of retroviral nucleic acid sequences | |
MX2016009243A (es) | Métodos de mutagénesis. | |
MX2020007078A (es) | Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1. | |
AU2017286122A1 (en) | Use of Cpf1 endonuclease for plant genome modifications | |
GB2527450A (en) | Compositions and methods of nucleic acid-targeting nucleic acids | |
MX352568B (es) | Molecula de acido nucleico de cadena simple para el control de la expresion de genes. | |
EP3413908A4 (en) | METHOD AND COMPOSITIONS FOR MODIFYING A MUTANT DYSTROPHINE IN A CELL GENOM | |
EP3699280A3 (en) | Novel cas9 systems and methods of use | |
NZ734019A (en) | Novel micro-dystrophins and related methods of use | |
WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
EP3633032A3 (en) | Novel cas9 proteins and guiding features for dna targeting and genome editing | |
MX2019015188A (es) | Inserciones de adn no virales orientadas. | |
GB2600568A8 (en) | Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing | |
AU2018339164A1 (en) | Artificial genome manipulation for gene expression regulation | |
BR112021010781A2 (pt) | Silenciamento genético por meio de edição de genoma | |
MX2021012511A (es) | Delecion mediada por vector aav de punto activo mutacional grande para el tratamiento de distrofia muscular de duchenne. | |
MY198780A (en) | Process for the biological production of methacrylic acid and derivatives thereof | |
EP3752179A4 (en) | GENE EDITING WITH HOMOLOGY-INDEPENDENT UNIVERSAL GENOME ENGINEERING TECHNOLOGY | |
EA033036B1 (ru) | Регулирование процессов в биореакторе | |
MX2020002038A (es) | Métodos para el tratamiento de distrofia muscular. | |
WO2021026081A3 (en) | Rna guide genome editing in citrus using crispr-ribonucleoprotein complexes | |
EA201991647A1 (ru) | ОПТИМИЗИРОВАННАЯ СТРАТЕГИЯ МОДИФИКАЦИЙ, ВЫЗЫВАЮЩИХ ПРОПУСК ЭКЗОНА, С ПРИМЕНЕНИЕМ CRISPR/Cas9 С ТРОЙНЫМИ НАПРАВЛЯЮЩИМИ ПОСЛЕДОВАТЕЛЬНОСТЯМИ |